Treatment with temozolomide in aggressive pituitary tumors – data from a survey by the German Pituitary Study Group

Sven-Martin Schlaffer, Michael Buchfelder, Michael Droste, Uwe Elbelt, Rolf Buslei & Stephan Petersenn
Objective: Patients with aggressive pituitary tumors still present a major challenge due to limited efficacy of surgery and radiotherapy, and the absence of any effective chemotherapy. Recently, temozolomide (TMZ) has been suggested as a potential treatment. Method: The German Pituitary Study group[for full text, please go to the a.m. URL]